VP20621: Phase II data

A double-blind, international Phase II trial in 168 patients previously treated for CDI with oral vancomycin or metronidazole showed that all doses of once-daily VP20621 met the primary endpoint of increasing the proportion of patients with non-toxigenic C. difficile detected in stool during the 14-day treatment period vs. placebo. Specifically, non-toxigenic C. difficile was detected in stool culture in 54% of patients receiving 104 spores of VP20621 for 7 days (followed by placebo for 7 days), 79% of patients receiving 107 spores of VP20621 for 7 days (followed by placebo for 7...